The small basic protein p14 ARF , encoded by one of the alternative transcripts from the human INK4A/ARF locus, interferes with MDM2-mediated ubiquitination of the p53 tumour suppressor protein. The resultant stabilization of p53 leads to increased expression of p53-regulated genes, such as MDM2 itself and the cyclin-dependent kinase inhibitor p21
Introduction
Normal cells have the capacity to resist the potentially tumorigenic consequences of, for example, virus infection, DNA damage, or inappropriate proliferative signals, by undergoing cell cycle arrest or apoptosis mediated primarily by the p53 protein (reviewed in Evan and Littlewood, 1998; Giaccia and Kastan, 1998; Levine, 1997) . The prominent role of p53 in tumour suppression is underlined by the fact that it is the most frequent known target of genetic alterations in human cancers (Hollstein et al., 1994; Soussi et al., 2000) . In addition to mutations that directly compromise p53 function, abnormalities aecting upstream and downstream components of the p53 pathway are also common. For example, MDM2, which serves as a direct counterbalance to p53, by blocking its transcriptional activation function and promoting its turnover (Ashcroft and Vousden, 1999) , is over-expressed in some tumours as a result of gene ampli®cation (Momand et al., 1998) . Conversely, p14 ARF , which binds to and functionally antagonizes MDM2, is deleted or methylated in many human cancers (Ruas and Peters, 1998) . Moreover, although point mutations are rarely found in the ®rst exon of p14 ARF , they occur frequently in the second exon. The functional impact of these lesions remains uncertain, however, because p14 ARF is encoded by an unusual locus in which a common second exon is decoded in dierent reading frames to produce two structurally and functionally distinct proteins (Ruas and Peters, 1998; Sharpless and DePinho, 1999; Sherr, 1998) . Mutations in the shared second exon, which occur, for example, in the germline of familial melanoma kindreds, have the potential to aect both gene products and the question remains whether some of these mutations target p14 ARF as well as, or instead of the p16
INK4a tumour suppressor. Under normal circumstances, p53 and MDM2 are maintained at low levels by a negative feedback loop in which p53 transcriptionally activates MDM2, while MDM2 promotes p53 degradation, by acting as an E3 ubiquitin ligase and contributing to the shuttling of p53 to the cytoplasm (Ashcroft and Vousden, 1999; Vogelstein et al., 2000) . Diverse stresses cause the posttranslational activation of p53 by blocking its turnover and increasing its transcriptional activity. The resulting biological output can be complex, depending on the cellular context and transcriptional targets. For example, activation of p21 CIP1 would be expected to lead to cell cycle arrest whereas activation of Bax would be pro-apoptotic (El-Deiry et al., 1993; Miyashita and Reed, 1995) . Since ARF has been shown to bind directly to MDM2, leading to stabilization of p53 (Kamijo et al., 1998; Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) , it is potentially an intermediary in at least some of the pathways that are known to engage p53, such as aberrant proliferative signals or enforced E2F-1 expression (Sherr, 1998) . The simplest explanation for ARF function is that it inhibits the ubiquitin ligase activity of MDM2, and Oncogene (2002) there is evidence for this both in vivo and in vitro (Honda and Yasuda, 1999; Midgley et al., 2000; Xirodimas et al., 2001) . A more complex model has been proposed in which ARF sequesters MDM2 in the nucleolus, causing physical separation of MDM2 from p53 (Lohrum et al., 2000; Weber et al., 1999) . However, in some settings at least, it is clear that ARF can stabilize endogenous MDM2 and p53 without quantitative relocation of either protein (Llanos et al., 2001) .
Initial characterization of both p19 ARF and p14 ARF indicated that the region of each protein speci®ed by exon 1b could perform all the known functions of the full length protein (Quelle et al., 1997; Stott et al., 1998; Zhang et al., 1998) . More detailed studies on mouse p19 ARF suggested that binding to MDM2 is mediated by two co-operating sites within the aminoterminal 37 residues of ARF (Weber et al., 2000) , whereas in dierent studies, interactions with MDM2 have been ascribed to the ®rst 14, 15, 22 and 29 residues of human p14 ARF Llanos et al., 2001; Lohrum et al., 2000; Midgley et al., 2000; Rizos et al., 2000; Weber et al., 2000) . However, functional contributions of residues encoded by exon 2 of p14 ARF have not been uniformly excluded (Lohrum et al., 2000; Zhang and Xiong, 1999) . A complicating issue has been the parallel interest in mapping sequences responsible for nucleolar localization of ARF, and their potential overlap with MDM2-interacting domains. We recently provided evidence that presumptive nucleolar localization motifs in p14 ARF are context dependent and that segments of the protein that do not accumulate in the nucleolus remain capable of stabilizing p53 (Llanos et al., 2001) . In the present study, we sought to systematically map the region of p14 ARF responsible both for MDM2 binding and p53 stabilization using a series of overlapping peptides representing the residues encoded by exon 1b and a combination of amino-and carboxyterminal deletions of the full-length p14 ARF protein. The data are consistent with a model in which the amino-terminal half of p14 ARF makes multiple contacts with MDM2 rather than binding via de®ned or recognizably conserved domains in the primary sequence.
Results

Mapping of MDM2 interacting domains in p14
ARF by peptide scanning
Published studies have established that the residues of p14 ARF or p19 ARF , encoded exclusively by the ®rst exon, are able to bind MDM2, stabilize p53 and elicit cell cycle arrest via the up-regulation of p21 CIP1 (Eymin et al., 2001; Llanos et al., 2001; Lohrum et al., 2000; Quelle et al., 1997; Rizos et al., 2000; Stott et al., 1998; Zhang et al., 1998) . To try to de®ne the MDM2 interacting domain(s) with greater precision, we synthesized a series of 10 peptides spanning the ®rst 65 amino acids of p14 ARF . Each peptide comprised 20 residues, overlapped its neighbours by 15 residues (Figure 1a) , and was biotinylated at its amino terminus to allow anity puri®cation on streptavidin-agarose beads. The peptides were mixed with 35 S-methioninelabelled MDM2 or p53 prepared by coupled transcription and translation in rabbit reticulocyte lysates, and the amount of labelled protein recovered on the streptavidin-coated beads was assessed by SDS ± PAGE and autoradiography. Peptides number 1 through 4 showed a signi®cant capacity to bind to MDM2, compared to the background with beads alone (Figure  1b) , and none of the peptides bound signi®cantly to p53. The simplest interpretation of these data would be that the region of p14 ARF common to all four peptides (residues 16 ± 20) must be responsible for binding to MDM2. However, these residues are not well conserved between human, mouse and rat ARF ( Figure  1c ), and we noted that peptide number 2 consistently showed reduced binding relative to that of adjacent peptides. Moreover, when we tried to con®rm the importance of this region, for example by making individual alanine substitutions of amino acids P17, P18 and R19 in the context of the whole protein, these changes had no discernible impact on MDM2 binding (data not shown).
An alternative interpretation would be that there is more than one MDM2 binding site within the region of p14 ARF encompassed by the four peptides. Attempts to localize the contact residues more precisely, using shorter peptides (10 amino acids), proved fruitless as the peptides did not form suciently stable associations with MDM2 to register in the assay. Conversely, a single peptide spanning the entire 35 amino acid region (peptide number 11) did not show a signi®cantly higher anity for MDM2 than, for example, peptides number 1 and 4 (Figure 1d ). Thus, we were unable to ®nd evidence for co-operativity between separate domains of p14 ARF in this in vitro system, although dilution series con®rmed that the binding assays were not saturated.
Mapping MDM2 binding sites in p14
ARF using amino terminal deletions
Having established that domains within the ®rst 35 amino acids of p14 ARF could mediate binding to MDM2 in vitro, we sought to delineate the critical residues more precisely in the context of the full length protein. As a starting point, a series of plasmids were constructed encoding p14 ARF -GFP fusion proteins with increasingly extensive amino-terminal deletions, as depicted schematically in Figure 2 . To standardize the nomenclature, each deletion mutant is described in terms of the numbers of ARF residues retained in the protein, with the implicit assumption that there is always an amino-terminal methionine. The resultant plasmids were expressed in the U2OS osteosarcoma cell line by transient transfection, along with a plasmid encoding full length human MDM2. Note that U2OS cells contain wild-type pRb and p53 but do not express any endogenous p14 ARF (Stott et al., 1998) . The cell lysates were immunoprecipitated with a polyclonal antiserum against the carboxy-terminal domain of p14 ARF and the amount of associated MDM2 was assessed by immunoblotting with a mouse monoclonal antibody. Surprisingly, deletion of the ®rst 19 residues of p14 ARF (20 ± 132) had no discernible impact on the interaction with MDM2 ( Figure 3 ). Moreover, a protein lacking the ®rst 35 amino acids (36 ± 132) still retained a signi®cant capacity to interact with MDM2. We therefore extended the initial deletion series to determine the point at which interaction with MDM2 was completely abrogated. Whereas 46 ± 132 still showed some binding to MDM2, 51 ± 132 did not ( Figure 3 ). Taken together, the data imply that while the ®rst 35 amino acids of p14 ARF contain a domain or domains that are sucient to mediate MDM2 binding, they are not absolutely required for the interaction, and an additional binding site must be present between residues 36 and 50. Presumably, the corresponding synthetic peptides did not adopt a suitable conformation to register in the binding assay in Figure 1 . The reduced binding of 31 ± 132 compared to 20 ± 132 would be consistent with the idea that there are two binding domains in this amino terminal region, and at face value therefore our data suggest that p14 ARF makes multiple (at least three) contacts with MDM2. Previous studies have suggested that p14 ARF function may not strictly correlate with its ability to bind to MDM2, and that subcellular localization is also important. We therefore subjected the amino-terminal deletion series to a number of additional tests of p14 ARF function. As we previously reported, the ability of MDM2 to promote the proteasome-mediated destruction of p53 in co-transfection assays (Haupt et al., 1997; Kubbutat et al., 1997) is completely blocked by co-expression of p14 ARF (Stott et al., 1998) . Progressive deletion of amino-terminal residues reduced the ability of ARF to protect p53 in this assay (Figure 4) , and the pattern of decline almost exactly paralleled the step-wise diminution in MDM2 binding seen in Figure 3 .
A limitation of this type of assay is that the ARF deletion mutants, detected using an antibody against the carboxy-terminal GFP tag, did not show uniform levels of expression, as previously observed (Llanos et al., 2001) . To try to achieve more quantitative comparisons, we devised an assay in which the transcriptional activity of p53, resulting from ARFmediated stabilization, could be related to the expression levels of the various ARF deletion mutants. U2OS cells were co-transfected with ARF-encoding plasmids and a reporter construct in which p53-responsive sequences from the Bax gene promoter were used to drive expression of luciferase (Miyashita and Reed, 1995) . The luciferase activities attributable to ARFmediated stabilization of p53 were then normalized to the GFP-associated¯uorescence derived from each ARF mutant. As before, the apparent activity of p14 ARF declined with progressive amino-terminal deletions ( Figure 5 ) and the pattern of decline was very similar to that of MDM2 binding and p53 stabilization shown in Figures 3 and 4 . Taken together, the data imply that the abilities of ARF to bind MDM2 and activate p53 are non-separable.
However, there have been a number of reports suggesting that a key property of p14 ARF is its ability to sequester MDM2 in the nucleolus (Lohrum et al., 2000; Weber et al., 1999 Weber et al., , 2000 . Although we have argued to the contrary (Llanos et al., 2001) , we felt it was important to determine whether the reduced ability of amino-terminally deleted forms of ARF to activate Figure 3 Co-precipitation of MDM2 and ARF deletion mutants. Following co-transfection of U2OS cells with MDM2 and the indicated ARF plasmids, cell lysates were immunoprecipitated with a polyclonal rabbit antiserum against the carboxy-terminal domain of p14 ARF . The immunoprecipitates were resolved by SDS ± PAGE in a 12% gel and immunoblotted with mouse monoclonal antibodies against MDM2 (upper panel) or p14 ARF (middle panel). Samples of cell lysate were also analysed directly to control for the levels of MDM2 expressed in the transfected cells (lower panel). EGFP is a control plasmid encoding enhanced green¯uorescent protein Figure 4 Stabilization of p53 by ARF deletion mutants. U2OS cells were co-transfected with plasmids encoding p53, MDM2 and the various ARF±GFP constructs and controls as indicated by + and 7. Equivalent amounts of cell lysate were fractionated by SDS ± PAGE and immunoblotted for p53 (upper panel) and GFP (lower panel) as indicated Figure 5 Activation of p53-dependent transcription by ARF deletion mutants. U2OS cells were co-transfected with the indicated ARF±GFP fusions and a reporter construct in which the Bax promoter was used to drive expression of luciferase. After 48 h, cells were processed for measurement of luciferase activity and GFP¯uorescence, as described in Materials and methods. Relative luciferase activity represents promoter activity normalized against ARF±GFP expression levels p53 re¯ected dierences in their sub-cellular localization. This was facilitated by the carboxy-terminal GFP tag on each deletion mutant, allowing direct visualization of¯uorescence in the transiently transfected U2OS cells. In the event, all eight of the amino-terminally truncated forms of the protein were localized in the nucleolus, but with a signi®cant level of staining in the nucleoplasm (Figure 6 ). This is analogous to the pattern we observed previously for GFP fusion proteins incorporating residues 1 ± 64 of p14 ARF (exon 1b only) or residues 65 ± 132 (exon 2 only), with more obvious staining of the nucleoplasm than seen with full length ARF±GFP (Llanos et al., 2001) . Others have suggested that the amino-terminal 22 residues of p14 ARF contain a nucleolar localization signal and that removal of the ®rst 14 residues can signi®cantly compromise ARF location and function (Lohrum et al., 2000; Weber et al., 2000) . While our data do not exclude some contribution of amino-terminal residues to ARF localization, they demonstrate that removal of Figure 6 Subcellular localization of ARF±GFP fusion proteins. U2OS cells transfected with the indicated ARF plasmids were ®xed in paraformaldehyde and GFP-based¯uorescence was visualized by confocal microscopy. The corresponding phase contrast images reveal the number and location of the cells in each ®eld the putative signal has only a modest eect on the ratio of nucleolar to nucleoplasmic staining ( Figure 6 ) and on the ability of ARF to activate p53 ( Figure 5 ).
Further analyses of MDM2-binding domains in p14 ARF
The amino-terminal deletion series was designed to complement previously described forms of p14 ARF that could be broadly classi®ed as carboxy-terminal deletions (Figure 2 ). These included plasmids encoding residues 1 ± 64 (exon 1b only) and 1 ± 29 of p14 ARF , fused to GFP (Llanos et al., 2001) . In co-precipitation assays with monoclonal antibodies against either MDM2 (Figure 7a ) or GFP ( Figure 7b ) these two deletion mutants appeared to bind to MDM2 with the same eciency as a fusion protein incorporating all of p14 ARF . Thus, under conditions of over-expression, the presence or absence of residues 30 ± 64 appeared to make little dierence to the interaction of the fusion proteins with MDM2, raising doubts about the signi®cance of this weakly conserved region of the protein. To try to resolve this issue, we constructed a fusion protein with only residues 36 ± 64 fused to GFP (see Figure 2) , and found that this protein did not coprecipitate with MDM2 when co-expressed in U2OS cells (Figure 8a, lane 3) . We were therefore faced with a situation in which proteins encompassing residues 36 ± 64 alone or residues 65 ± 132 alone did not show signi®cant binding activity (Figure 8a lanes 3 and 6) yet when these residues were contiguous, as in 36 ± 132, MDM2 binding was restored (Figure 8a, lane 4) .
A plausible explanation would be that there are separate MDM2 interaction domains within residues 36 ± 64 and 65 ± 132 but that neither registers in the assays used here unless combined within the same protein. However, when the transiently transfected cells were examined by immuno¯uorescence, we noted that with the 36 ± 64 construct, GFP¯uorescence was distributed throughout the cell, with a substantial proportion in the cytoplasm, whereas 36 ± 132 was clearly nuclear and nucleolar (Figure 8b ). An alternative explanation, therefore, would be that 36 ± 64 is simply in the wrong place to interact with MDM2. To test this idea, a further derivative was constructed containing residues 36 ± 64 of ARF together with three copies of the SV40 nuclear localization signal (36NLS) as previously described (Llanos et al., 2001) . Signi®cantly, the 36 ± 64 ± 36NLS protein was nuclear and nucleolar (Figure 8b) , and was capable of interacting with MDM2 (Figure 8a, lane 5) , whereas a protein comprising only GFP and the 36NLS motif was not (not shown). This result implies that residues 36 ± 64 are indeed capable of interacting with MDM2 provided that they are expressed in the cell nucleus.
Discussion
The low degree of conservation among known orthologues of p14 ARF , the absence of related proteins in existing databases, and the relative rarity of tumour speci®c mutations that speci®cally aect ARF have made it dicult to identify residues or domains that are critical for its function. A typical experimental approach, therefore, has been to determine whether speci®c segments of the protein will perform some or all of its known functions. Here we have chosen direct binding to MDM2, stabilization of p53, and activation of p53-dependent transcription as the functional readouts and the data we present suggest that these functions are inseparable. What emerges is a model in which the amino terminal region of the protein, encoded by exon 1b, makes multiple contacts with MDM2 such that no single domain can be de®ned as both necessary and sucient for ARF function.
Our initial binding assays (Figure 1 ) con®rmed published studies that a synthetic peptide corresponding to the ®rst 20 amino acids of p14 ARF is capable of associating with MDM2 (Midgley et al., 2000) . Indeed, the previous studies showed that peptide number 1 could block MDM2-mediated ubiquitination of p53 and there is therefore little doubt that this domain is functionally relevant. Where our results dier, however, is that we also detected binding with additional peptides, suggesting that the interacting sequences may extend downstream of residue 20. A recent study using shorter ARF peptides (15 residues) drew similar conclusions and suggested that the amino terminus of ARF contains two MDM2 interacting motifs . However, it has to be recognized that isolated peptides may not adopt an appropriate conformation or show a high enough anity to register in the dierent binding assays used in dierent studies.
To con®rm our ®ndings, we constructed a version of p14 ARF that lacked the ®rst 19 residues (20 ± 132). This protein proved capable of binding to MDM2 (Figure  3 ), stabilizing p53 (Figure 4 ) and increasing its transcriptional activity ( Figure 5 ) and with the caveat that these assays rely on over-expression, we found little evidence for functional impairment relative to the full length protein. Others have suggested that removal of the amino terminal 14 residues signi®cantly Figure 7 Interaction between MDM2 and amino-terminal domains of ARF. U2OS cells were co-transfected with MDM2 and the indicated ARF constructs, including residues 1 ± 64 and 1 ± 29 fused to GFP. In (a), the cell lysates were immunoprecipitated with an antiserum against MDM2 and immunoblotted with monoclonal antibodies against GFP (upper panel) or MDM2 (lower panel). In (b), the lysates were immunoprecipitated with a monoclonal antibody against GFP and immunoblotted for MDM2 (upper panel) or GFP (lower panel) compromises the ability of human p14 ARF to localize to the nucleolus and to stabilize p53 (Weber et al., 2000) , but neither eect was apparent under the conditions used here. We did, however, observe reduced activity with increasing extents of amino terminal truncation, consistent with the notion that residues between 20 and 35 also contribute to the interaction with MDM2. To our surprise, complete ablation of ARF function required the removal of the ®rst 50 residues suggesting a much more extensive interacting domain than previously surmised. Note, however, that we found no evidence that ARF residues encoded by exon 2 (65 ± 132) bind signi®cantly to MDM2 or stabilize p53 (Figures 3, 4 and 5 and Llanos et al., 2001) .
Previous studies have drawn con¯icting conclusions about the contribution that exon 2-encoded residues make to ARF function (Llanos et al., 2001; Lohrum et al., 2000; Quelle et al., 1997; Rizos et al., 2000; Stott et al., 1998; Zhang and Xiong, 1999; Zhang et al., 1998) . One of the confounding factors is the widely held belief that because ARF is a predominantly nucleolar protein, it must function in the nucleolus. While it is clear that exon 2 encodes a highly basic domain that can contribute to nucleolar localization (LindstroÈ m et Rizos et al., 2000; Zhang and Xiong, 1999) , we have recently challenged these conceptions by showing that ARF can function in the nucleoplasm and that the presumptive nucleolar localization signals are highly dependent on the context in which they are placed (Llanos et al., 2001) . Nevertheless, we con®rmed that all of amino-terminally truncated forms of ARF studied here showed nucleolar and nucleoplasmic localization, as detected using the GFP tag.
The one exception to this rule was the fusion protein containing residues 36 ± 64 fused to GFP, which had been constructed in an attempt to verify that these residues contain an independent MDM2-binding domain. This protein was distributed throughout the cell and while not excluded from the nucleus, it clearly did not accumulate in the nucleus or nucleolus. It was also unable to bind detectably to MDM2 as judged by co-immunoprecipitation. However, when redirected to the nucleus, by addition of the 36NLS motif, this protein was capable of associating with MDM2 ( Figure  8 ). It therefore seems plausible that the functional dierences between 36 ± 64 and 36 ± 132 can be explained by nuclear import signals encoded by exon 2. Indeed, when residues 65 ± 132 were placed amino terminal to 36 ± 64, the resultant fusion protein was nuclear and functional, albeit with reduced activity relative to the natural con®guration (data not shown). While these ®ndings are consistent with the notion that the ARF-MDM2 interaction takes place in the nucleoplasm, as we have previously argued (Llanos et al., 2001 ), they do not formally exclude the possibility that motifs within residues 36 ± 64 and 65 ± 132 collaborate in binding to MDM2.
This issue remains a matter of some debate because of the organization of the INK4a/ARF locus and the suspicion that germline and tumour-speci®c mutations in exon 2 might aect both gene products. While most studies conclude that the residues encoded by exon 1b are sucient for ARF function, these have generally been based on over-expression and do not rule out some contribution from exon 2, such as the provision of a nucleolar localization signal (Eymin et al., 2001; Llanos et al., 2001; Lohrum et al., 2000; Quelle et al., 1997; Rizos et al., 2000; Stott et al., 1998; Zhang et al., 1998) . However, at face value the published data require that ARF-MDM2 interactions rely on cooperating domains that occur in dierent locations in the mouse and human proteins. Data on mouse ARF have been interpreted in terms of two MDM2 interaction domains within exon 1b, one of which overlaps with a nucleolar localization signal (Weber et al., 2000) whereas the data on human ARF imply contributions from both exons (LindstroÈ m et al., 2000; Lohrum et al., 2000; Rizos et al., 2000; Weber et al., 2000; Zhang and Xiong, 1999) . As it is hard to imagine how this would have arisen during evolution of this unusual locus, we favour a dierent view in which the interaction of ARF with MDM2 is mediated by multiple contact residues in the amino-terminal half of ARF, potentially within the ®rst 50 residues. While our data are consistent with the suggestion that there are two MDM2 binding`motifs' at residues 3 ± 10 and 21 ± 29 of human ARF , there is no recognizable version of the proposed consensus between residues 30 and 64.
Our ®ndings could provide a logical explanation for the rarity with which missense mutations in exon 1b have been recorded in human tumours. Point mutations are unlikely to have a signi®cant destabilizing eect on the ARF-MDM2 interaction and all of the single amino acid substitutions that we have analysed to date have proved indistinguishable from wild-type, at least based on the assays currently at our disposal. We are, however, aware of two frameshift mutations in exon 1b, one a single base deletion in a colon carcinoma cell line (Burri et al., 2001 ) and the other a 16 bp insertion in familial melanoma (Rizos et al., 2001) . These would eectively truncate ARF sequences after residues 33 and 21, respectively. Evaluation of the latter variant suggested that the protein is nonfunctional, despite retaining the amino-terminal domain of ARF, presumably because it is predominantly cytoplasmic (Rizos et al., 2001) .
A striking feature of the primary sequence of ARF is the high proportion of arginine residues, often in pairs and often adjacent to hydrophobic amino acids. In evolutionary terms, it seems that the amino acid composition of the protein is conserved, despite considerable drift in the primary sequence. It is intriguing that this highly basic protein associates with an acidic domain in MDM2, raising the possibility that the interaction is at least in part dependent on electrostatic forces . Our ®ndings that these proteins make multiple contacts highlight the frustrating reality that it may be impossible to identify the relevant residues in ARF by standard molecular biology approaches. However, recent biophysical analyses have concluded that while the amino terminal domain of ARF is largely unstructured in aqueous solution, interaction with the relevant domains of MDM2 induces the formation of extended b-strands which assemble co-operatively into large supramolecular structures DiGiammarino et al., 2001) . It seems that a detailed understanding of how ARF and MDM2 interact will require a crystal structure of the complex.
Materials and methods
Peptide binding assays
Oligopeptides corresponding to short regions of p14 ARF were synthesized by the ICRF Protein and Peptide Chemistry Laboratory. Peptides incorporating 10 or 20 amino acids were made on an ABI 432A synthesizer whereas the 35 residue peptide was made using a Model 431A updated PE Biosystems Solid Phase Synthesizer. All peptides were aminoterminally biotinylated and two residues of aminohexanoic acid were included as a spacer between the biotin and the p14 ARF derived sequences (see Figure 1a) . Freeze dried peptides were reconstituted at a concentration of 5 mg/ml in dimethylsulphoxide (DMSO) and working solutions prepared by dilution in phosphate-buered saline (PBS) to give a ®nal peptide concentration of 175 mM. The peptides were bound to streptavidin conjugated agarose beads (Pierce) for 1 h at room temperature at a ®nal peptide concentration of 4.7 mM, in PBS containing 3% bovine serum albumin (BSA) and protease inhibitors (0.1 mM sodium¯uoride, 2 mg/ ml aprotinin and 100 mg/ml phenylmethylsulphonyl¯uoride). The beads were then washed three times with PBS.
The relevant coding regions of human MDM2 and p53 were transferred into the pcDNA3 vector to enable in vitro transcription and translation using the TNT T7 Quick Coupled system (Promega). The proteins were labelled by incorporation of 35 S-methionine and cysteine (Promix, Amersham). Radiolabelled products were diluted 1 : 3 in PBS plus 3% BSA and protease inhibitors and 20 ml of this mixture was added to the washed packed beads and allowed to bind for 1 h at 48C. The beads were washed four times with 1.56PBS containing 0.2% Triton X-100 and boiled in 26 Laemmli buer for analysis by SDS ± PAGE.
Plasmid construction
The vectors used to express p14 ARF -GFP fusion proteins, 1 ± 64 ± GFP and 1 ± 29 ± GFP were previously described (Llanos et al., 2001) . Amino-terminal deletion mutants of p14 ARF were generated by PCR using the p14 ARF cDNA in the pcDNA3 vector as template (Stott et al., 1998) XhoI and BamHI sites were introduced into the 5' and 3' ends, respectively, by incorporation of the relevant sequences in the oligonucleotide primers. The PCR products were digested with XhoI and BamHI and ligated into similarly digested EGFPN1 vector (Clontech) creating an in-frame fusion between the carboxyterminus of p14 ARF and enhanced green uorescent protein (GFP). The 5' PCR primers for each construct were as follows: 11 ± 132 -CCACTCGAGATGAT-TCGGCGCGCGTGCGGCCCG, 20 ± 132 -CCACTCGAG-ATGGTGAGGGTTTTCGTGGTTCACATCCC, 31 ± 312 -CCACTCGAGATGACGGG GGA GTG GGC AGCG CCA -GG, 36 ± 132 -CCACTCGAGATGGCGCCAGGGGCGC-CCGCCGCTGTGG, 41 ± 132 -CCACTCGAGATGGCCG-CTGTGGCCCTCGTGC, 46 ± 132 -CCACTCGAGATGGT-GCTGATGCTACTGAGGAGCC, 51 ± 132 -CCACTCGA-GATGAGGAGCCAGCGTCTAGGGCAGC. Each primer contained an ATG (shown in bold) to serve as a translation initiation codon and all of the derivatives were generated with the same 3' primer: CCGGATCCCCGCCAGGTCCACG-GGCAGACGGC.
A similar strategy was used to generate 36 ± 64 ± GFP using the same 5' primer as 36 ± 132, and CCGGATCCCCT-GGTCTTCTAGGAAGCGGCTGCTG as the 3' primer. This latter construct was further modi®ed by insertion of annealed complementary oligonucleotides encoding three copies of the SV40 nuclear localization signal (36NLS) and BamHI-compatible overhangs as follows: GATCTC-GATCCAAAAAAGAAGAGAAAGGTAGATCCAAAAA -AGAAGAGAAAGGTAGAT CCAAAAAA GAAGA GAA -AGGTG and GATCCACCTTTCTCTTCTTTTTTGGATC-TACCTTTCTCTTCTTTTTTGGATCTACC TTTCTC TTC-TTTTTTGGATCGA.
Co-immunoprecipitation assays
U2OS cells were co-transfected with expression vectors encoding ARF±GFP derivatives of human MDM2 (pCMVMDM2) using standard calcium phosphate precipitation. After 48 h, cell lysates were prepared in NP40 lysis buer (50 mM Tris.HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P40, 0.1 mM sodium¯uoride, 2 mg/ml aprotinin, 100 mg/ml PMSF). Samples (1 ml) containing 1 mg of protein were immunoprecipitated overnight. ARF was precipitated using either of two rabbit polyclonal antisera: JR14, which recognizes the carboxy terminal region of p14 ARF (Llanos et al., 2001) or DP54-75, raised against amino acids 54 ± 75, which span the junction between exon 1b and exon 2 (generously provided by David Parry, DNAX Research Institute). GFP was immunoprecipitated with the mouse monoclonal antibody 3E1 (provided by the ICRF antibody production service). MDM2 was immunoprecipitated with mouse monoclonal antibody SMP14 conjugated to agarose beads (Santa Cruz). The precipitated proteins were fractionated by SDS ± PAGE in 12% gels and analysed by immunoblotting (Bates et al., 1994) . p14 ARF was detected using the mouse monoclonal antibody 4c6/4 (Llanos et al., 2001) , MDM2 with the mouse monoclonal antibody IF2 (Oncogene Sciences) and GFP with the mouse monoclonal antibody 3E1.
p53 stabilization assay
The ability of various p14 ARF fusion proteins to block MDM2-mediated destruction of p53 was assessed by cotransfecting U2OS cells with 1.5 mg pCB6+p53 and 5 mg of pCMV-MDM2 vectors in the presence or absence of 3.5 mg of the relevant p14 ARF expression vector (Stott et al., 1998) . After 48 h, p53 levels were assessed by Western blot analysis using the mouse monoclonal antibody DO-1 (Santa Cruz). Expression levels of the fusion proteins were monitored using the anti-GFP antibody 3E1.
p53 transcriptional activation assay
The ability of the p14 ARF deletion mutants to enhance p53 transcriptional activity was assayed by co-transfecting U2OS cells with 5 mg of each ARF plasmid and 2 mg of a p53 reporter plasmid, pGL3-Bax-luc, containing the human Bax promoter upstream of a luciferase reporter (Miyashita and Reed, 1995) . Cell lysates were prepared 48 h after transfection using reporter lysis buer (Promega), and luciferase activity was assessed using the Luciferase Reporter Assay System from Promega. Light emission was measured using an MLX microtitre plate luminometer (Dynex Technologies). GFP¯uorescence was measured in the same lysates using the Cyto¯uor multiwell plate reader series 4000 (PerSeptive Biosystem). Relative promoter activity was calculated from the ratio of luciferase to GFP levels.
Immunofluorescence U2OS cells were grown on coverslips and transfected with the appropriate expression vectors. After 48 h, the cells were washed and ®xed in 3% paraformaldehyde. Coverslips were mounted on glass slides and the GFP fusion proteins were visualized by direct¯uorescence using an Axioplan-2 (Zeiss) confocal microscope and Zeiss LSM-510 confocal software.
